Tier 2 — strong

Quercetin as a possible complementary agent for early-stage COVID-19: Concluding results of a randomized clinical trial

Francesco Di Pierro, Amjad Khan, Somia Iqtadar, Sami Ullah Mumtaz, Muhammad Nabeel Akbar Chaudhry, Alexander Bertuccioli, Giuseppe Derosa, Pamela Maffioli, Stefano Togni, Antonella Riva, Pietro Allegrini, Martino Recchia, Nicola Zerbinati
Frontiers in pharmacology 2022 13:1096853

Bibliography

PubMed
PMID 36712674
PubMed Central
PMC9880293
DOI
10.3389/fphar.2022.1096853
Funding
Funding was not specified in the indexed record or the disclosure metadata available for this entry.
Competing interests
Reported disclosure: FDP belongs to the Scientific Board of Pharmextracta. AB is a Pharmextracta scientific advisor. ST, PA, and AR belong to the Scientific Board of Indena. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Study snapshot

DesignRandomized open-label adjunctive trial
ModelHuman intervention research
Sample100 COVID-19 outpatients; 50 per group
InterventionQuercetin Phytosome 500 mg three times/day in week 1 and twice/day in week 2, plus usual care
Duration2 weeks
EndpointsSymptoms and quality of life

What the study showed, in plain terms

Published in 2022, this source examined immunity and respiratory health. Design: Randomized open-label adjunctive trial. Sample/model: 100 COVID-19 outpatients; 50 per group. The exposure or intervention was Quercetin Phytosome 500 mg three times/day in week 1 and twice/day in week 2, plus usual care. Follow-up or treatment period: 2 weeks.

Early viral-test negativity and symptom resolution favored the supplement arm.

Formulation-specific open-label study. This is the concluding report of a registered program with earlier pilot reporting, not an independent replication of that pilot.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin for Immune Health, Colds and COVID-19. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • Early viral-test negativity and symptom resolution favored the supplement arm.
  • The recorded outcome domains were Symptoms and quality of life.
  • The result applies to the tested exposure: Quercetin Phytosome 500 mg three times/day in week 1 and twice/day in week 2, plus usual care; 2 weeks.

What this study can and cannot tell us

  • Formulation-specific open-label study. This is the concluding report of a registered program with earlier pilot reporting, not an independent replication of that pilot.
  • Without a sufficiently blinded concurrent control, time effects, expectations, co-interventions and regression toward the mean can explain part of an apparent improvement.
  • Companion or correction records are linked below. They should not be counted automatically as independent replications; see the individual source notes for the relationship.
  • Source basis: Source check: accessible full text and indexed metadata. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 2
Potential Clinical Benefits of Quercetin in the Early Stage of COVID-19: Results of a Second, Pilot, Randomized, Controlled and Open-Label Clinical Trial
Francesco Di Pierro et al. · International journal of general medicine · 2021
Tier 2
Immune Preconditioning with Oral Quercetin Supplement and COVID-19 mRNA Vaccine Responses: A Randomized, Double-Blind, Placebo-Controlled Trial
Shokichi Takahama et al. · The Journal of nutrition · 2026
Tier 2
The therapeutic efficacy of quercetin in combination with antiviral drugs in hospitalized COVID-19 patients: A randomized controlled trial
Mojtaba Shohan et al. · European journal of pharmacology · 2022
Tier 2
Oral Co-Supplementation of Curcumin, Quercetin, and Vitamin D3 as an Adjuvant Therapy for Mild to Moderate Symptoms of COVID-19-Results From a Pilot Open-Label, Randomized Controlled Trial
Amjad Khan et al. · Frontiers in pharmacology · 2022

Citation network

Articles citing this research paper

2 articles

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology